The lancet oncology

• Latest
• Best
• Search…

• The lancet oncology · Jul 2013

  Comment

  EGFR-directed treatments in SCCHN.

  no abstract available

  read more… mark as read…

• The lancet oncology · Jul 2013

  Comment

  Tumour angiogenesis: an elusive target in castration-resistant prostate cancer.

  no abstract available

  expand abstract… mark as read…

• The lancet oncology · Jul 2013

  NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer.

  no abstract available

  read more… mark as read…

• The lancet oncology · Jul 2013

  Comment

  Personalisation of colorectal cancer screening.

  no abstract available

  read on… or not…

• The lancet oncology · Jul 2013

  Randomized Controlled Trial Multicenter Study Comparative Study

  Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.

  Therapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the population in which most benefit is derived is uncertain. Our aim was to assess the addition of panitumumab to irinotecan in pretreated advanced colorectal cancer. ⋯ Cancer Research UK, Amgen Inc.

  explore further… or not…